Shared on 23 Oct 25

Fair value Decreased 1.06%

Takeda Pharmaceutical's analyst price target has been revised downward from ¥5,002.88 to ¥4,949.73, as analysts' slightly reduced revenue growth projections are now balanced by improved profit margin expectations. What's in the News Takeda and Innovent Biologics entered a strategic global partnership to accelerate development of next-generation cancer therapies, including several investigational immuno-oncology and antibody-drug conjugate medicines.

Shared on 09 Oct 25

Fair value Decreased 1.05%

Pipeline Advances In Rare Diseases Will Revitalize Future Healthcare Markets

Analysts have modestly lowered their price target for Takeda Pharmaceutical, reducing the fair value estimate from ¥5,056.07 to ¥5,002.88. They cite slightly softer outlooks for revenue growth and profit margins as the reason for this adjustment.

Shared on 31 Aug 25

Fair value Increased 1.01%

Pipeline Advances In Rare Diseases Will Revitalize Future Healthcare Markets

Takeda Pharmaceutical's consensus price target saw a modest increase to ¥5,056, primarily reflecting a slight upward revision in forecasted annual revenue growth. What's in the News Takeda released positive Phase 3 data for oveporexton (TAK-861), an investigational orexin receptor 2 agonist, in narcolepsy type 1; both studies met all endpoints and showed significant improvements in sleepiness and cataplexy frequency versus placebo.

Shared on 01 May 25

Fair value Increased 3.89%